Drugs / ST-01156
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07197554 | Dec 2025 → Dec 2029 expected | Ewing sarcoma, biliary tract cancer, hepatocellular carcinoma | SEED Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-04-22 | SEED Therapeutics, Inc. | Results SEED Therapeutics Reports Tumor Eradication in a Neuroblastoma In Vivo Model with Clinical-Stage RBM39 Molecular Glue Degrader ST-01156 seedtherapeutics.com ↗ |
| 2025-11-12 | SEED Therapeutics, Inc. | Regulatory SEED Therapeutics Receives IND Clearance from China’s NMPA for ST-01156 seedtherapeutics.com ↗
SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, today announced that China’s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ST-01156. |
| 2025-09-23 | SEED Therapeutics, Inc. | Regulatory SEED Therapeutics Completes $30 Million Series A-3 Financing seedtherapeutics.com ↗
FDA clearance of our IND is a defining milestone for SEED, marking our transition into a clinical-stage company. |
| 2025-08-11 | SEED Therapeutics, Inc. | Regulatory FDA Clears IND for SEED Therapeutics’ RBM39 Degrader ST-01156 seedtherapeutics.com ↗
SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ST-01156. |
| 2025-01-28 | SEED Therapeutics, Inc. | Regulatory SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors seedtherapeutics.com ↗
King of Prussia, PA – January 28, 2025 – SEED Therapeutics Inc. (“SEED”), a biotechnology company pioneering the discovery of molecular glues for targeted protein degradation (TPD) using its proprietary RITE3™ platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Orphan Drug designations to SEED’s ST-01156 molecular glue. |
All press releases naming this drug 8 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ST-01156 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07197554 ↗ |
| Action | Inhibit | “an inhibitor of RBM39” NCT07197554 ↗ |
| Modality | Small molecule | “Small Molecule RBM39 Degrader” NCT07197554 ↗ |
| Route | Oral | “administered orally” NCT07197554 ↗ |
| Target | RBM39 | “degrader of RBM39” NCT07197554 ↗ |